St. John’s wort and drug interactions
This article was originally published in The Tan Sheet
Executive Summary
Cancer patients, oncologists should cooperate to "develop a plan regarding which CAM practices to pursue and which to put aside altogether," NCCAM Director Stephen Straus, MD, and staff clinician Patrick Mansky, MD, advise in Aug. 21 Journal of the National Cancer Institute. "No matter how beneficial some approaches may appear to be, they are not all safe," NIH officials stress in editorial accompanying study on use of St. John's wort by cancer patients. Conducted by a Dutch research group, randomized, cross-over study of five cancer patients found anti-tumor activity of cancer drug irinotecan is negatively affected by concurrent use of St. John's wort. Findings were released at the American Association for Cancer Research annual meeting in April (1"The Tan Sheet" April 15, 2002, p. 13)...
You may also be interested in...
St. John’s Wort Multi-Center Trial In Mild Depression Underway
A multi-center clinical trial on St. John's wort in mild depression is underway with $4 mil. in funding from three National Institutes of Health divisions, according to the National Center for Complementary and Alternative Medicine
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.